These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. DiPiazza AT; Leist SR; Abiona OM; Moliva JI; Werner A; Minai M; Nagata BM; Bock KW; Phung E; Schäfer A; Dinnon KH; Chang LA; Loomis RJ; Boyoglu-Barnum S; Alvarado GS; Sullivan NJ; Edwards DK; Morabito KM; Mascola JR; Carfi A; Corbett KS; Moore IN; Baric RS; Graham BS; Ruckwardt TJ Immunity; 2021 Aug; 54(8):1869-1882.e6. PubMed ID: 34270939 [TBL] [Abstract][Full Text] [Related]
13. The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial. Zhou C; Qiu Y; Wang J; Zhong X; Zhu X; Huang X; Yang L; Ji Q; Zhou F; Wu S; Yang M; Zhang J; Liu K; Ji L; Yang H; Li C; Zhao Y Emerg Microbes Infect; 2024 Dec; 13(1):2320913. PubMed ID: 38860446 [TBL] [Abstract][Full Text] [Related]
14. Rational design of a single-component mRNA vaccine against orthopoxvirus and SARS-CoV-2. Yang Y; Zhao X; Li Y; Zai X; Wang X; Zhang Y; Wang X; Lv P; Zhang J; Hou L; Xu J; Chen W Sci China Life Sci; 2024 Jun; 67(6):1311-1313. PubMed ID: 38443664 [No Abstract] [Full Text] [Related]